



## Sun Pharmaceuticals

STOCK INFO.	BLOOMBERG
BSE Sensex: 16,416	SUNP IN
	REUTERS CODE
S&P CNX: 4,870	SUN.BO

30 May 2008

Buy

Rs1,403

Previous Recommendation: Buy

	YEAR END	NET SALES (RS M)	PAT (RS M)	EPS (RS)	EPS GROWTH (%)	P/E (X)	P/BV (X)	ROE (%)	ROCE (%)	EV/ SALES	EV/ EBITDA
Equity Shares (m)	193.4										
52-Week Range	1,520/855										
1,6,12 Rel. Perf. (%)	3/40/12										
M.Cap. (Rs b)	271.3										
M.Cap. (US\$ b)	6.4										
	03/08A*	32,909	14,869	71.8	89.6	19.5	5.5	36.8	34.2	7.2	15.3
	03/09E	31,778	11,370	54.9	-23.5	25.5	4.6	19.7	21.2	7.2	19.0
	03/09E*	40,205	16,521	79.8	11.1						
	03/10E	36,888	13,660	66.0	20.1	21.3	3.9	20.1	21.5	5.9	15.3
	03/10E*	39,183	14,692	70.9	-11.1						

\* - Includes Para-IV upsides

Sun Pharma's 4QFY08 performance was above estimates. Key highlights:

- Net sales grew by 133% to Rs12.39b while PAT grew 241% to Rs7.22b. Revenues & PAT were boosted by exclusivity-based supplies of Pantoprazole & Oxcarbazepine (we estimate sales at Rs5.6b with PAT contribution of Rs3.4b). Adjusted for these one-offs, net sales grew by 27% to Rs6.75b while PAT grew by 59% to Rs3.3b.
- Guidance:** Management has guided for 18-20% top-line growth for FY09E excluding US sales, while Caraco has guided for 25% top-line growth in the US including Para-IV upsides.
- Update on Taro acquisition:** Taro's directors have rejected SPIL's merger offer citing reasons of undervaluation. SPIL is currently exploring various options to pursue the merger.

We have upgraded our core EPS estimates by 13-15% each for FY09E and FY10E. An expanding generic portfolio coupled with change in product mix in favor of high-margin exports is likely to bring in long-term benefits for SPIL. Its ability to sustain high growth rates at superior margins even on a high base is a clear positive. With the domestic business progressing well and increasing traction on the US front (both in Caraco and from India), the possibility of a rapid scale-up over the next couple of years is high. Key drivers for future include ramp-up in US, the expected value unlocking by leveraging acquired companies (Able Labs & Valeant) and monetization of the Para-IV pipeline. Based on our revised estimates, SPIL is valued at 25.5x FY09E and 21.3x FY10E earnings (excl Para-IV upsides which have a DCF value of Rs25/share). We maintain **Buy**.

### QUARTERLY PERFORMANCE (CONSOLIDATED)

(Rs Million)

Y/E MARCH	FY07				FY08				FY07	FY08
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
<b>Net Revenues</b>	<b>4,987</b>	<b>5,239</b>	<b>5,263</b>	<b>5,313</b>	<b>6,153</b>	<b>6,465</b>	<b>7,902</b>	<b>12,389</b>	<b>20,792</b>	<b>32,909</b>
YoY Change (%)	31.8	27.4	24.2	33.5	23.4	23.4	50.1	133.2	30.4	58.3
<b>EBITDA</b>	<b>1,811</b>	<b>1,708</b>	<b>1,733</b>	<b>1,545</b>	<b>2,148</b>	<b>2,409</b>	<b>3,547</b>	<b>7,407</b>	<b>6,798</b>	<b>15,511</b>
Margins (%)	36.3	32.6	32.9	29.1	34.9	37.3	44.9	59.8	32.7	47.1
Depreciation	202	204	212	201	226	230	245	268	818	969
Net Other Income	274	402	636	942	606	111	179	556	2,253	1,451
<b>PBT</b>	<b>1,883</b>	<b>1,906</b>	<b>2,157</b>	<b>2,286</b>	<b>2,528</b>	<b>2,290</b>	<b>3,481</b>	<b>7,695</b>	<b>8,233</b>	<b>15,994</b>
Tax	2	-22	-29	-18	98	1	116	270	-67	485
Rate (%)	0.1	-1.1	-1.3	-0.8	3.9	0.0	3.3	3.5	-0.8	3.0
<b>Profit after Tax</b>	<b>1,882</b>	<b>1,928</b>	<b>2,186</b>	<b>2,304</b>	<b>2,430</b>	<b>2,289</b>	<b>3,365</b>	<b>7,425</b>	<b>8,300</b>	<b>15,509</b>
Share of Minority Partner	115	64	198	183	158	104	181	197	559	640
<b>Adj Net Profit</b>	<b>1,767</b>	<b>1,864</b>	<b>1,989</b>	<b>2,121</b>	<b>2,272</b>	<b>2,185</b>	<b>3,184</b>	<b>7,228</b>	<b>7,741</b>	<b>14,869</b>
YoY Change (%)	29.9	26.1	35.8	48.4	28.6	17.2	60.1	240.8	35.0	92.1
Margins (%)	35.4	35.6	37.8	39.9	36.9	33.8	40.3	58.3	37.2	45.2

E: MOST Estimates; \* Quarterly results have been recasted and hence do not tally with full year results

### Pantoprazole and Oxcarbazepine exclusivities drive revenue growth

SPIL's net sales grew 133% to Rs12.39b while PAT grew 241% to Rs7.22b. Revenues & PAT were boosted by exclusivity-based supplies of Pantoprazole & Oxcarbazepine (not quantified by mgt. but we estimate sales at Rs5.6b with PAT contribution of Rs3.4b). Adjusted for these one-offs, net sales grew by 27% to Rs6.75b (vs estimates of Rs6.8b) while PAT grew by 59% to Rs3.3b (vs estimates of Rs2.3b). Other income was higher by Rs750m vs our estimates. Core revenue growth was led by 23% growth in formulation exports to Rs2.4b and a 93% increase in API exports to Rs926m resulting in overall export growth of 37% to Rs3.4b.

SUN PHARMA - BUSINESS BREAK UP (RS M)

	4QFY08	4QFY07	YOY (%)	2QFY08	QOQ (%)
<b>Domestic Sales</b>					
Formulation	3,615	3,122	15.8	3,758	-3.8
Bulk	218	139	57.0	177	23.1
Others	1	4	-88.6	2	-77.3
<b>Total Domestic Sales</b>	<b>3,834</b>	<b>3,265</b>	<b>17.4</b>	<b>3,937</b>	<b>-2.6</b>
Contribution (%)	30.0	57.0		47.4	
<b>International sales</b>					
Formulation	8,021	1,966	308.0	3,902	105.6
Bulk	926	479	93.4	466	98.8
Others	18	15	20.3	5	270.8
<b>Total Internat. sales</b>	<b>8,964</b>	<b>2,459</b>	<b>264.5</b>	<b>4,372</b>	<b>105.0</b>
Contribution (%)	70.0	43.0		52.6	
<b>Gross Sales</b>	<b>12,798</b>	<b>5,725</b>	<b>123.6</b>	<b>8,309</b>	<b>54.0</b>

Source: Company/Motilal Oswal Securities

### Caraco continues with good performance

Caraco's net sales for 4QFY08 grew by 485% to US\$192m led mainly by the shared 180-day exclusivity on Pantoprazole & Oxcarbazepine. PAT grew by only 20% for the quarter despite very strong top-line growth due to significantly lower margins on Sun Pharma products. While the company has not given any details, we believe that distributed products (including Sun Pharma's Para-III & Para-IV products) are likely to have contributed approximately US\$150m to the revenues for the quarter. Excluding contribution from distributed products, Caraco is likely to have recorded 25%+ growth in top-line. Caraco has commenced expansion of its existing facility and expects

to commission the new facility by end-2008. This implies that it expects more product-flow in the coming years.

### Guides for 18-20% top-line growth ex-US, Caraco to grow top-line by 25%

SPIL has guided for 18-20% top-line growth for FY09E excluding US sales, while Caraco has guided for 25% top-line growth in the US including upsides from Para-IV launches like generic Protonix, Effexor XR and Ethylol. Hence, overall revenues for FY09E are expected to record 21-22% growth. R&D expenses are estimated at 7-8% of sales.

### Generic pipeline being strengthened, more visibility on Para-IV pipeline

SPIL (along with Caraco) has 104 ANDAs (across 89 products) awaiting approval with the US FDA. It filed 48 ANDAs for FY08. We note that there is now increased visibility on the company's Para-IV pipeline with the company receiving 3 approvals with shared exclusivity in FY08. These include approvals for generic Protonix, Trileptal, Ethylol and Exelon (cumulative ~US\$3.4b branded sales), of which it has already launched Trileptal, Protonix and Ethylol and entered into an out-of-court settlement for Exelon. It has also received a "will-not-sue" covenant from Wyeth for Effexor XR (US\$2.6b market) and is awaiting final US FDA approval for this product.

Teva has already entered into an out-of-court settlement for its capsule version of generic Effexor in the past while Osmotica Pharma has recently settled out-of-court with Wyeth for the tablet version (same as that of SPIL). SPIL's product may not get an AB rating as the filing is for tablets while the RLD is for capsules. Based on our DCF valuation, we attach a value of Rs25/share to SPIL's Para-IV pipeline.

### Generic Protonix launch – A well planned strategy

We believe that SPIL's Para-IV filings reflect a well planned strategy for patent challenges without taking any major risks (shared exclusivities will involve lower risks in case of adverse litigation outcome). This is clearly visible in the launch-at-risk of generic Protonix. SPIL launched its version

post the launch by Teva and the launch of authorized generic by the innovator thus ensuring that it will not be liable for triple damages in case of an adverse case ruling on Protonix.

### **SPIL may stop selling generic Protonix after 1QFY09 to minimize risks**

Caraco has guided for 25% top-line growth for FY09E. SPIL management has indicated in 4QFY08 conference call that it will retain generic Protonix revenues at 4QFY08 levels even for 1QFY09. We believe that Caraco has given a very conservative guidance given the significant upsides expected from generic Protonix and Effexor XR. Caraco's muted guidance can be explained by either of the below mentioned events:

1. SPIL stops selling generic Protonix post 1QFY09 to minimize risks
2. SPIL's Effexor XR US FDA approval gets delayed

Since we do not have clarity on the timeline for Effexor XR approval, we have assumed that SPIL may stop selling generic Protonix post 1QFY09.

### **Update on Taro Pharma acquisition**

Taro's Board of Directors has recently rejected SPIL's merger offer despite the hike in offer price from US\$7.75 to US\$10.25 per share. Taro has cited that, given the improved financial condition of the company, SPIL's offer undervalues Taro and hence it has terminated that merger agreement. SPIL has various options to pursue the merger and that it may resort to legal action against Taro.

We believe that Taro acquisition would have benefited SPIL in the long-term, given Taro's presence in low-competition specialized segments like Dermatology and Paediatrics in the US coupled with a recently concluded capex of US\$225m, which is yet to be fully utilized. SPIL owns option to acquire Taro promoter's stake (approx. 5m shares) at US\$7.75/share within the next 30 days as per the merger agreement. This can cost the company an additional

US\$39m and will raise its stake in Taro to about 47% (with 64% voting rights). It has till date, invested about US\$97m in Taro for 34.4% stake. We await further clarity on this from SPIL and Taro. Our estimates do not take into account the impact of any potential merger.

As per the original merger agreement, the Taro acquisition would have cost SPIL about US\$450-500m. SPIL management had, in the past, guided for a payback period of about 5.5-6 years implying US\$83m annual PAT for Taro (likely to be back-ended and may not be visible in the first year of acquisition).

Taro Pharma has a pipeline of over 100 approved ANDAs and 23 ANDAs pending US FDA approval. It also has one NDA application for which it has already received the approvable letter from the US FDA. It has presence in low-competition segments like Dermatology, Paediatrics and has capabilities to develop and file complex products. Operations are reasonably backward integrated into manufacture of APIs.

### **Past acquisitions to be leveraged from FY09 onwards**

Product filings are likely to pick up out of the acquired Valeant facility (situated at Ohio, USA) and Able Labs facility. The Valeant facility gives SPIL the capability to manufacture liquids and semi-solids. It is pertinent to note that Caraco does not have such capabilities and that it would have been economically uncompetitive for SPIL to transport such products from India to USA. The acquisition of Valeant's Hungary facility is expected to help SPIL in filings for the European markets.

We believe that SPIL is cautiously acquiring generic assets (with specific focus on distress assets). This is evident from SPIL's acquisitions of Valeant Pharma's facilities in Hungary and USA (both costing about US\$10m each). The acquisition of Able Labs assets is also a step in this direction.

### Revising estimates

Based on the better than expected 4Q performance (even excl Para-IV upsides), we have upgraded our core EPS estimates by 13-15% each for FY09E and FY10E. We expect SPIL to record core EPS of Rs54.9 and Rs66 for FY09E and FY10E respectively. Including upsides from visible Para-IV opportunities, we estimate EPS of Rs80 and Rs71 respectively. Our estimates assume that SPIL will stop selling generic Protonix in the US post 1QFY09 to minimize risks.

#### REVISED FORECAST (RS M)

	FY09E			FY10E		
	REV	OLD	CHG (%)	REV	OLD	CHG (%)
Net Sales	31,778	30,743	3.4	36,888	36,704	0.5
Net Profit	11,370	10,055	13.1	13,660	11,858	15.2
EPS (Rs)	54.9	48.5	13.1	66.0	57.3	15.2

*Estimates exclude Para-IV upsides*

*Source: MOSL*

### Valuation and outlook

An expanding generic portfolio coupled with change in product mix in favor of high-margin exports is likely to bring in long-term benefits for SPIL. SPIL's ability to sustain high growth rates at superior margins even on a high base is a clear positive. With the domestic business progressing well and increasing traction on the US front (both in Caraco and from India), the possibility of a rapid scale-up over the next couple of years is high.

Key drivers for future include ramp-up in US, the expected value unlocking by leveraging acquired companies (Able Labs & Valeant) and monetization of the Para-IV pipeline. Based on our revised estimates, SPIL is valued at 25.5x FY09E and 21.3x FY10E earnings (excl Para-IV upsides which have a DCF value of Rs25/share). We maintain **Buy** with revised target price of Rs1,600.

## Sun Pharmaceuticals: an investment profile

### Company description

Sun Pharma is among the largest players in the domestic formulations market and the most profitable one. It makes and markets specialty medicines and APIs for chronic therapy areas such as cardiology, psychiatry, neurology, etc. Sun has forayed into regulated markets by acquiring majority stake in Caraco Pharma and intends to look at inorganic means to get a foothold in Europe, as well.

### Key investment arguments

- ☞ Ability to identify niches in long term therapy areas with high entry barriers and build strong franchise to ensure sustainable growth and high margins.
- ☞ Well-diversified portfolio de-risks its against any slowdown in a particular category.
- ☞ Among the few Indian companies to have a direct presence in the US market (through Caraco).

### Key investment risks

- ☞ Highly dependent on new product launches for growth in domestic market.
- ☞ Has not demonstrated the ability to build any big brand so far – a key driver for growth going forward.
- ☞ Capability to scale up exports, particularly to unregulated markets, is yet to be fully demonstrated.

### Recent developments

- ☞ Taro Pharma directors have rejected SPIL's merger proposal citing reasons of undervaluation.

### Valuation and view

- ☞ Multiples of 25.5x FY09E and 21.3x FY10E earnings do not reflect the potential leverage arising out of acquired companies, ramp up in US business and monetization of large Para-IV opportunities.
- ☞ Re-iterate **Buy** with revised price target of Rs1,600

### Sector view

- ☞ Regulated markets would remain the key sales and profit drivers in the medium term. Europe is expected to emerge as the next growth driver, particularly for companies with a direct marketing presence.
- ☞ We are overweight on companies that are towards the end of the investment phase, with benefits expected to start coming in from the next fiscal.

#### COMPARATIVE VALUATIONS

		SUN PHARMA	RANBAXY	DRL
P/E (x)	FY09E	25.5	27.1	18.9
	FY10E	21.3	23.8	15.3
P/BV (x)	FY09E	4.6	5.9	2.4
	FY10E	3.9	5.2	2.1
EV/Sales (x)	FY09E	7.2	2.9	2.1
	FY10E	5.9	2.5	1.8
EV/EBITDA (x)	FY09E	19.0	18.5	13.7
	FY10E	15.3	14.8	11.3

#### SHAREHOLDING PATTERN (%)

	MAR-08	DEC-07	MAR-07
Promoter	63.7	65.6	68.3
Domestic Inst	5.0	4.9	4.5
Foreign	21.6	19.4	16.8
Others	9.8	10.2	10.5


#### EPS: MOST FORECAST VS CONSENSUS (RS)

	MOST FORECAST	CONSENSUS FORECAST	VARIATION (%)
FY09	54.9	68.4	-19.7
FY10	66.0	68.9	-4.3

#### TARGET PRICE AND RECOMMENDATION

CURRENT PRICE (RS)	TARGET PRICE (RS)	UPSIDE (%)	RECO.
1,403	1,600	14.0	Buy

#### STOCK PERFORMANCE (1 YEAR)



CONSOLIDATED INCOME STATEMENT						(Rs Million)					
Y/E MARCH	2006	2007	2008E	2009E	2010E						
<b>Net Sales</b>	<b>15,945</b>	<b>20,792</b>	<b>32,909</b>	<b>31,778</b>	<b>36,888</b>						
Change (%)	39.3	30.4	58.3	-3.4	16.1						
Total Expenditure	11,050	14,069	17,398	19,774	22,731						
<b>EBITDA</b>	<b>4,895</b>	<b>6,723</b>	<b>15,511</b>	<b>12,004</b>	<b>14,157</b>						
Margin (%)	30.7	32.3	47.1	37.8	38.4						
Depreciation	610	813	969	1,044	1,127						
<b>EBIT</b>	<b>4,285</b>	<b>5,910</b>	<b>14,543</b>	<b>10,960</b>	<b>13,030</b>						
Int. and Finance Charges	0	0	0	0	0						
Other Income - Rec.	1,684	2,425	1,451	1,638	1,938						
PBT	5,969	8,334	15,994	12,598	14,968						
Tax	239	-67	485	504	599						
Tax Rate (%)	4.0	-0.8	3.0	4.0	4.0						
<b>Profit after Tax</b>	<b>5,730</b>	<b>8,401</b>	<b>15,509</b>	<b>12,094</b>	<b>14,369</b>						
Change (%)	43.2	46.6	84.6	-22.0	18.8						
Margin (%)	36	40	47	38	39						
Less: Mionrity Interest	-3	559	640	723	708						
<b>Net Profit</b>	<b>5,733</b>	<b>7,842</b>	<b>14,869</b>	<b>11,370</b>	<b>13,660</b>						

CONSOLIDATED BALANCE SHEET						(Rs Million)					
Y/E MARCH	2006	2007	2008E	2009E	2010E						
Equity Share Capital	929	967	1,036	1,036	1,036						
Preference Share Capital	14	14	14	14	14						
Total Reserves	14,959	26,747	52,013	61,467	72,655						
<b>Net Worth</b>	<b>15,902</b>	<b>27,728</b>	<b>53,062</b>	<b>62,517</b>	<b>73,704</b>						
Minority Interest	332	438	1,078	1,801	2,510						
Deferred Liabilities	1,053	895	895	1,235	1,460						
Total Loans	18,745	11,144	1,500	1,500	1,500						
<b>Capital Employed</b>	<b>36,031</b>	<b>40,205</b>	<b>56,535</b>	<b>67,053</b>	<b>79,174</b>						
Gross Block	12,342	14,252	14,952	16,202	17,202						
Less: Accum. Deprn.	3,779	4,738	5,706	6,750	7,877						
<b>Net Fixed Assets</b>	<b>8,563</b>	<b>9,514</b>	<b>9,246</b>	<b>9,452</b>	<b>9,325</b>						
Capital WIP	414	608	608	608	608						
Goodwill	507	697	697	697	697						
Investments	3,541	2,543	4,892	4,892	4,892						
<b>Curr. Assets</b>	<b>26,520</b>	<b>29,889</b>	<b>45,793</b>	<b>55,978</b>	<b>69,210</b>						
Inventory	5,117	6,645	3,858	4,754	5,518						
Account Receivables	3,609	6,789	7,213	6,965	8,085						
Cash and Bank Balance	15,323	13,802	29,943	39,645	50,655						
<b>Curr. Liability &amp; Prov.</b>	<b>3,515</b>	<b>3,046</b>	<b>4,700</b>	<b>4,574</b>	<b>5,558</b>						
Account Payables	2,279	2,966	2,157	2,657	3,084						
Provisions	1,236	80	2,543	1,917	2,473						
<b>Net Current Assets</b>	<b>23,006</b>	<b>26,843</b>	<b>41,092</b>	<b>51,404</b>	<b>63,653</b>						
<b>Appl. of Funds</b>	<b>36,031</b>	<b>40,205</b>	<b>56,535</b>	<b>67,053</b>	<b>79,174</b>						

E: Most Estimates

Estimates exclude Para-IV upsides, historic numbers include Para-IV upsides

RATIOS					
Y/E MARCH	2006	2007	2008E	2009E	2010E
<b>Basic (Rs)</b>					
<b>EPS</b>	<b>30.9</b>	<b>40.6</b>	<b>71.8</b>	<b>54.9</b>	<b>66.0</b>
<b>Fully Diluted EPS</b>	<b>27.7</b>	<b>37.9</b>	<b>71.8</b>	<b>54.9</b>	<b>66.0</b>
Cash EPS	30.6	41.8	76.5	59.9	71.4
BV/Share	85.5	143.3	256.1	301.8	355.8
DPS	5.5	6.7	10.5	7.9	10.2
Payout (%)	20.4	17.7	16.4	15.8	17.2
<b>Valuation (x)</b>					
P/E	50.7	37.0	19.5	25.5	21.3
Cash P/E	45.8	33.6	18.3	23.4	19.6
P/BV	16.4	9.8	5.5	4.6	3.9
EV/Sales	17.0	12.8	7.2	7.2	5.9
EV/EBITDA	55.4	39.6	15.3	19.0	15.3
Dividend Yield (%)	0.4	0.5	0.7	0.6	0.7
<b>Return Ratios (%)</b>					
RoE	42.1	35.9	36.8	19.7	20.1
RoCE	18.6	22.7	34.2	21.2	21.5
<b>Working Capital Ratios</b>					
Asset Turnover (x)	0.4	0.5	0.6	0.5	0.5
Debtor (Days)	87	126	84	84	84
Inventory (Days)	124	123	45	58	58
Working Capital T/O (Days)	555	497	481	623	664
<b>Leverage Ratio</b>					
Debt/Equity (x)	1.2	0.4	0.0	0.0	0.0

CASH FLOW STATEMENT						(Rs Million)					
Y/E MARCH	2006	2007	2008E	2009E	2010E						
Oper. Profit/(Loss) before Tax	4,168	6,723	15,511	12,004	14,157						
Interest/Dividends Recd.	1,025	2,425	1,451	1,638	1,938						
Direct Taxes Paid	-165	-91	-485	-164	-374						
(Inc)/Dec in WC	-3,177	-5,358	1,891	-609	-1,239						
<b>CF from Operations</b>	<b>1,852</b>	<b>3,699</b>	<b>18,369</b>	<b>12,869</b>	<b>14,482</b>						
(inc)/dec in FA	-3,384	-2,148	-700	-1,250	-1,000						
(Pur)/Sale of Investments	5,173	998	-2,349	0	0						
<b>CF from investments</b>	<b>1,789</b>	<b>-1,150</b>	<b>-3,049</b>	<b>-1,250</b>	<b>-1,000</b>						
Issue of Shares	0	5,015	13,008	1	1						
(Inc)/Dec in Debt	801	-7,601	-9,644	0	0						
Interest Paid	-156	0	0	0	0						
Dividend Paid	-772	-1,483	-2,543	-1,917	-2,473						
<b>CF from Fin. Activity</b>	<b>-127</b>	<b>-4,070</b>	<b>821</b>	<b>-1,916</b>	<b>-2,473</b>						
<b>Inc/Dec of Cash</b>	<b>3,514</b>	<b>-1,521</b>	<b>16,141</b>	<b>9,703</b>	<b>11,010</b>						
Add: Beginning Balance	11,809	15,323	13,802	29,943	39,645						
<b>Closing Balance</b>	<b>15,323</b>	<b>13,802</b>	<b>29,943</b>	<b>39,645</b>	<b>50,655</b>						

Note: Cashflows do not tally due to acquisition

**N O T E S**



For more copies or other information, contact

**Institutional:** Navin Agarwal. **Retail:** Manish Shah

Phone: (91-22) 39825500 Fax: (91-22) 22885038. E-mail: inquire@motiloswal.com

**Motilal Oswal Securities Ltd, 3rd Floor, Hoechst House, Nariman Point, Mumbai 400 021**

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Motilal Oswal Securities Limited (*hereinafter referred as MOST*) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form.

The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon such. MOST or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MOST and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

**Disclosure of Interest Statement**

**Sun Pharmaceuticals Industries**

1. Analyst ownership of the stock	No
2. Group/Directors ownership of the stock	No
3. Broking relationship with company covered	No
4. Investment Banking relationship with company covered	No

This information is subject to change without any prior notice. MOST reserves the right to make modifications and alternations to this statement as may be required from time to time. Nevertheless, MOST is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.